Miflonide Breezhaler

Budesonide, the active ingredient in Miflonide Breezhaler, is a inhaled corticosteroid presented as an inhalation powder for inhalation use. It reduces airway inflammation and is used in the long‑term management of asthma and chronic obstructive pulmonary disease (COPD) in adults and children. GNH USA supplies Miflonide Breezhaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Miflonide Breezhaler delivers budesonide to the airways, providing anti‑inflammatory control for chronic respiratory diseases. - Asthma: improves symptom control and reduces the frequency of exacerbations. - Chronic obstructive pulmonary disease (COPD): helps maintain lung function and decreases exacerbation risk. - Maintenance therapy in chronic respiratory disease: provides daily anti‑inflammatory treatment to sustain airway patency.

Common Side Effects: - Oral thrush: fungal infection of the mouth or throat. - Hoarseness: voice changes after inhalation. - Cough: irritation of the airway during use. - Throat irritation: mild soreness or discomfort. Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing. - Adrenal suppression: reduced endogenous cortisol production. - Pneumonia: lower respiratory infection, especially in COPD patients.

Before initiating therapy, consider the following precautions: - Assess infection risk: evaluate for active respiratory infections. - Monitor growth in children: long‑term corticosteroid use may affect growth velocity. - Use mouth rinse: rinse and expectorate after each inhalation to reduce local effects. - Avoid abrupt discontinuation: taper under medical supervision to prevent adrenal insufficiency. - Store at room temperature: keep in original container, protect from moisture and heat.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): may increase systemic budesonide exposure. Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole, erythromycin): may modestly raise budesonide levels. - Diuretics: can exacerbate hypokalemia when combined with systemic steroids. - Anticholinergic bronchodilators: monitor for additive bronchial effects.